AstraZeneca to use ProBioGen’s GlymaxX technology for drug discovery
ProBioGen has agreed a multi-product commercial license with AstraZeneca to use the GlymaxX technology.
ProBioGen has agreed a multi-product commercial license with AstraZeneca to use the GlymaxX technology.
Leading researchers are warning of the dangers of a quiet epidemic of vitamin B12 deficiency in people who follow increasingly popular plant-based diets and explain how it can be addressed.
Microplastics – tiny pieces of plastic less than 5 mm in length – are everywhere, from bottled water to food to air. They have been found in the deepest part of the ocean and the top of Mount Everest. According to recent estimates, people consume tens of thousands of these particles each year, with unknown […]
A common strategy to make vaccines more powerful is to deliver them along with an adjuvant – a compound that stimulates the immune system to produce a stronger response.
To solve the mysteries of how learning and memory occur, Johns Hopkins Medicine scientists have created a system to track millions of connections among brain cells in mice – all at the same time – when the animals’ whiskers are tweaked, an indicator for learning.
PhoreMost, a UK-based biopharmaceutical company dedicated to developing drugs against intractable disease targets, and Polaris Quantum Biotech, a North Carolina-based quantum computing drug design company, will collaborate to study oncology targets currently considered undruggable.
Metrion Biosciences, a specialist ion channel contract research and drug discovery company, and Bioqube Ventures, a specialist European life sciences investment firm, have entered into a collaboration, backed by Bioqube Factory Fund I, to incubate a drug discovery research project targeting autoimmune diseases.
MolGen B.V., a provider of DNA / RNA extraction technology, has opened an office in London, UK. The new location will serve as a pivotal branch to provide laboratories in the UK with access to the company’s extraction DNA / RNA portfolio across diagnostics, pharma and the biotech industry. The opening of the London office […]
42 Technology (42T), FIND, the global alliance for diagnostics, and Rutgers University have worked together to develop an innovative stool sample processing kit that has played a central role in informing the World Health Organi-zation’s (WHO) recent policy update to improve the diagnosis of tuberculosis (TB) in children.
Insightful Science, a software company enabling the Cloud for Scientific Discovery, has acquired Protein Metrics, a leading provider of biopharmaceutical protein characterization and proteomics analysis software. The acquisition expands the company’s R&D value chain to widen the biopharmaceutical protein analysis arena, unblocking data analysis bottlenecks currently associated with large-scale protein studies.
November 2024
The leading international magazine for Clinical laboratory Equipment for everyone in the Vitro diagnostics
Beukenlaan 137
5616 VD Eindhoven
The Netherlands
+31 85064 55 82
info@clinlabint.com
PanGlobal Media is not responsible for any error or omission that might occur in the electronic display of product or company data.
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlyCookie settingsWe may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.
Privacy policy